Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19"

Affiliations

• ¹ From the Renal-Electrolyte and Hypertension Division (J.B.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
• ² Department of Biostatistics, Epidemiology, and Informatics (J.B.C., T.C.H.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
• ³ Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania (T.C.H., J.A.C.).
• ⁴ Section of Nephrology, Department of Pediatrics, Wake Forest School of Medicine and Brenner Children's Hospital, Winston-Salem, NC (A.M.S.).
• ⁵ Division of Public Health Sciences, Department of Epidemiology and Prevention, and Department of Surgery-Hypertension and Vascular Research, Wake Forest School of Medicine, Winston-Salem, NC (A.M.S.).
• ⁶ Division of Nephrology, Department of Medicine, Duke School of Medicine, Durham, NC (M.A.S.).
• ⁷ Renal Section, Durham Veterans Affairs Medical Center, NC (M.A.S.).
• ⁸ Division of Nephrology, Department of Medicine, University of Ottawa, Canada (S.H.).
• ⁹ Division of Health System Innovation and Research, Department of Population Health Sciences, University of Utah, Salt Lake City (A.P.B.).
• ¹⁰ Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor (J.B.B.).